Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Promem

Executive Summary

FDA's Peripheral & Central Nervous System Drugs Advisory Committee will review metrifonate (NDA 20-914) for treatment of mild to moderate dementia of the Alzheimer's type on Jan. 27. The following day, the committee will review Immunex' Novantrone (mitoxantrone, NDA 21-120) for treatment of secondary progressive multiple sclerosis ("The Pink Sheet" Dec. 13, 1999, p. 22). The meeting begins at 8:00 a.m. at the Hilton in Gaithersburg, Md. on both days
Advertisement

Related Content

Bayer ProMem delayed again
Bayer ProMem delayed again
FDA Advisory Cmte. Material Disclosure To Debut With Bayer ProMem Review
FDA Advisory Cmte. Material Disclosure To Debut With Bayer ProMem Review
Advertisement
UsernamePublicRestriction

Register

PS035361

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel